Please assess the completion status of the following clinical trial:

Trial Title: Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Definite MS as defined by revised McDonald criteria.~* Bilateral distal symmetric burning pain involving both feet for at least three months.~* Baseline weekly average pain rating equal to four or greater on 0-10 numerical scale.~* Stable MS medication and pain-related medications for 8 weeks prior to screening.~* Must come to Research Center for appointments~Exclusion Criteria:~* Topical treatment with lidocaine, capsaicin, or other topical analgesics within 3 months prior to screening.~* Any treatment with opioid analgesics or tramadol within 3 months prior to screening.~* Hypersensitivity to Lidoderm, lidocaine, or other local anesthetics.~* Hypersensitivity or inability to tolerate opioid analgesics.~* Current treatment with a total of 3 or more antidepressant or anticonvulsant drugs for pain.~* Current treatment with Class I anti-arrhythmic agents at baseline.~* Beck Depression Inventory score \> 16 or clinically significant depression or dementia.~* History of suicide attempt or current intent or plan.~* History of excessive alcohol use or any illicit drug use within the past 2 years.~* Lack of adequate birth control in pre-menopausal women of childbearing age.~* Other pain more severe than lower extremity burning pain.~* Open skin lesions in the area where the lidocaine patch is to be applied.~* Cancer within the previous 5 years other than skin cancer.~* MS exacerbation or any treatment with corticosteroids within 3 months prior to screening.~* History of peripheral neuropathy, lower limb amputation, or another neuromuscular syndrome or systemic disorder known to be associated with sensory neuropathy.~* Does not meet criteria of baseline lab values at screening visit.~* Nerve conduction studies consistent with peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lidocaine 5% + placebo patch, ER and placebo pills (Type: ACTIVE_COMPARATOR): 5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period

Based on this trial design, predict the completion outcome and termination type (if applicable).